<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502709</url>
  </required_header>
  <id_info>
    <org_study_id>CVS-TMD-001</org_study_id>
    <nct_id>NCT01502709</nct_id>
  </id_info>
  <brief_title>Neurostimulation in Temporomandibular Disorders (TMD) Patients</brief_title>
  <acronym>CVS</acronym>
  <official_title>Randomized Blinded Placebo-Controlled Clinical Trial of Caloric Vestibular Neurostimulation in Patients With Chronic TMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to conduct a randomized blinded placebo-controlled clinical trial
      in patients with chronic TMD (N=20). Patients will be randomly assigned to receive either
      active treatment (caloric vestibular neurostimulation) or placebo. Data will be collected
      prior to and after treatment on thermal and mechanical pain thresholds, clinical signs and
      symptoms of TMD, and any adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Temporomandibular disorders (TMD) are musculoskeletal pain conditions characterized by pain
      in the temporomandibular joint and/or the masticatory muscles. TMD are amongst the most
      common chronic musculoskeletal conditions affecting 6 to 12% of the general population yet
      there are no medicines approved specifically for its treatment. TMD cause substantial
      suffering and TMD pain is the most common symptom that compels patients to seek therapy. One
      study found average ratings of pain intensity due to TMD of 4.3 on a 10-point scale, similar
      to the averages reported for chest pain and back pain. Studies consistently find that TMD has
      a pronounced impact on quality of life. Thus, a new successful approach to TMD therapy would
      have a significant clinical and economic impact.

      Caloric vestibular stimulation (CVS) is a routine diagnostic test for the assessment of
      vestibular function and Central nervous system pathology. It is usually conducted by
      instilling cold or warm water into the external ear canal and has been shown to activate
      anterior cingulate, temporoparietal and insular cortices. In addition to its use as a
      diagnostic test, CVS has also been shown to reduce pain in several chronic conditions
      including migraine, phantom limb pain, spinal cord injury, thalamic pain, and complex
      regional pain syndrome.

      Central sensitization is a common feature of the pain conditions shown to be alleviated by
      CVS. It is a dysfunctional state of the central nervous system in which pain is no longer
      coupled to a noxious peripheral stimulus. In the presence of central sensitization the
      response to a noxious stimulus is exaggerated and prolonged (hyperalgesia) and may involve
      areas outside the site of injury (secondary hyperalgesia). Pain can also arise spontaneously
      and can be elicited by innocuous stimuli (allodynia). While the neural mechanisms underlying
      the development of TMD are poorly understood, there is accumulating evidence that central
      sensitization plays a critical role in TMD pathogenesis. It has been proposed that there is a
      cyclical process in which TMD pain results in central sensitization that in turn predisposes
      patients to more pain. Thus any treatment that reverses central sensitization should in turn
      result in a decrease in pain.

      Caloric vestibular stimulation (CVS) is a safe and effective procedure used for the diagnosis
      of brainstem injury and for balance assessment. As noted already, there have been intriguing
      observations in the literature suggesting that caloric vestibular stimulation can lead to the
      abatement of pain. When a caloric stimulation (warm or cool relative to body temperature) is
      applied to the ear canal, conduction (primarily via dense bone) to the inner ear, and in
      particular the prominence of the lateral semicircular canal (SCC), sets up convection
      currents in the endolymph. The resultant deformation of the cupula (membrane spanning the
      ampula of the SCC) leads to a phasic change in the tonic firing rate of hair cells at the
      base of the cupula, thereby altering the firing rate of the afferents of the vestibular nerve
      (thus a device delivering CVS may be viewed as a class of neurostimulator). The afferents map
      to nuclei in the brainstem (as well as some phylogenetically ancient, direct connections,
      e.g. to the thalamus and hippocampus) and then to the fastigial nuclei in the cerebellum. It
      is hypothesized that the method of action of CVS on pain relates to alteration of the phasic
      firing rate in the vestibular nerve afferents, which in turn alters the activation of the
      receiving areas (brainstem and cerebellum).

      The primary impediment to therapeutic applications of CVS has been the lack of a clinical
      device that provides controlled, prolonged, and repeatable caloric stimulation. The use of
      &quot;ice water&quot; irrigation using syringes or even the water/air irrigators used in balance
      studies are not practical for treatment regimens that extend up to 10 minutes. Further, the
      applicants believe that a controlled, time-varying thermal waveform is essential to avoid the
      effects of adaptation of the cupula, which then attenuates control of the phasic firing rate
      of the hair cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruiting difficulties
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Visual Analog Score (VAS) in Days 1-7 Post Treatment</measure>
    <time_frame>Daily Self-reports at Baseline and on Days 1 through 7</time_frame>
    <description>The mean of measures taken from days 1-7 was calculated. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. A decrease in score from Baseline represented treatment response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Time Spent in Pain From Days 1-7</measure>
    <time_frame>Days 1-7</time_frame>
    <description>The mean of measures taken from days 1-7 was calculated. Composite pain is a measure of mean pain intensity experienced and pain duration. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. Duration of pain ranges from 0 to 100% of a day. For example a pain free subject would report O pain intensity for 0% of the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Signs and Symptoms of Temporomandibular Disorder Based on Outcomes of Research Diagnostic Criteria (RDC) Exam</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>RDC for Temporomandibular disorders (TMD) is a reliable &amp; valid system for diagnosis of TMD, utilizing clinical procedures, diagnostic algorithms, and a dual-axis assessment comprising symptom history and physical exam. Signs and symptoms were evaluated by a trained professional and the history was obtained through use of questionnaires. In all sections and scales the higher the number reported corresponds to the more pain being experienced, therefore, a worse outcome. The clinical exam consists of facial, dental, and cervical evaluations including mandibular range of motion, Temporomandibular disorders Joint sound, and palpation of the orofacial muscles and temporomandibular joints (TMJ). Subjects are classified as TMD if they report pain in or around the temporomandibular joints or muscles of mastication for more than 3 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <arm_group>
    <arm_group_label>Caloric Vestibular Neurostimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received caloric vestibular neurostimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Caloric Vestibular Neurostimulation</intervention_name>
    <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
    <arm_group_label>Caloric Vestibular Neurostimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo device</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-65 years

          -  English speaking

          -  Females with chronic TMD

        Exclusion Criteria:

          -  History of any of the following: Terminal, progressive and /or unstable medical
             illness; Previous head or neck surgery for neoplasm; current chemotherapy or radiation
             therapy; facial trauma or orofacial surgery within the last 6 weeks; seizures, history
             of drug or alcohol abuse; Otologic disorders including chronic vertigo, chronic
             tinnitus, otitis external, otitis media, mastoiditis and tympanic membrane
             perforation; Stroke, transient ischemia attacks or Arnold- Chiari malformation;
             significant cardiac or respiratory disease; epilepsy or neurological disorders such as
             dementia, brain injury, and brain tumor

          -  Subjects who score â‰¥ 31 on the Becks depression inventory (performed at first
             appointment)

          -  History of or current destructive nerve therapies, defibrillator, pacemakers, deep
             brain stimulator, or Implantable nerve stimulators

          -  Utilization of other alternative or complementary therapies during the study period

          -  Participation in a clinical trial involving the use of a clinical devise in the last
             30 days

          -  Women who are currently pregnant or nursing.

          -  Patients who are left handed.

          -  Current orthodontic treatment.

          -  Use of an opiate in the 48 hour period preceding the baseline study visit

          -  The use of anti-histamines 6 hours before, during or immediately after the treatment
             period

          -  The use of anti-nausea or anti-vertigo drugs 6 hours before or during the treatment
             period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asma Khan, BDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill School of Dentistry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <results_first_submitted>August 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Asma Khan, BDS, PhD</investigator_full_name>
    <investigator_title>Assistant Professor UNC School of Dentistry</investigator_title>
  </responsible_party>
  <keyword>Single blind</keyword>
  <keyword>Randomized</keyword>
  <keyword>Controlled clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Caloric Vestibular Neurostimulation</title>
          <description>1 treatment of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>0 participants received placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caloric Vestibular Neurostimulation</title>
          <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>0 participants received placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="10.8"/>
                    <measurement group_id="B3" value="48" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Analog Score (VAS) in Days 1-7 Post Treatment</title>
        <description>The mean of measures taken from days 1-7 was calculated. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. A decrease in score from Baseline represented treatment response.</description>
        <time_frame>Daily Self-reports at Baseline and on Days 1 through 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neurostimulator</title>
            <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>0 participants received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Analog Score (VAS) in Days 1-7 Post Treatment</title>
          <description>The mean of measures taken from days 1-7 was calculated. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. A decrease in score from Baseline represented treatment response.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30">Data not analyzed because only complete information for 1 subject was available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Time Spent in Pain From Days 1-7</title>
        <description>The mean of measures taken from days 1-7 was calculated. Composite pain is a measure of mean pain intensity experienced and pain duration. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. Duration of pain ranges from 0 to 100% of a day. For example a pain free subject would report O pain intensity for 0% of the day.</description>
        <time_frame>Days 1-7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caloric Vestibular Neurostimulation</title>
            <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>0 participants received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Time Spent in Pain From Days 1-7</title>
          <description>The mean of measures taken from days 1-7 was calculated. Composite pain is a measure of mean pain intensity experienced and pain duration. Pain was assessed by using VAS score ranges from 0 millimeter (mm) = no pain to 100 mm = worst possible pain. Duration of pain ranges from 0 to 100% of a day. For example a pain free subject would report O pain intensity for 0% of the day.</description>
          <units>percentage of day in pain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77">Data not analyzed because only complete information for 1 subject was available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Signs and Symptoms of Temporomandibular Disorder Based on Outcomes of Research Diagnostic Criteria (RDC) Exam</title>
        <description>RDC for Temporomandibular disorders (TMD) is a reliable &amp; valid system for diagnosis of TMD, utilizing clinical procedures, diagnostic algorithms, and a dual-axis assessment comprising symptom history and physical exam. Signs and symptoms were evaluated by a trained professional and the history was obtained through use of questionnaires. In all sections and scales the higher the number reported corresponds to the more pain being experienced, therefore, a worse outcome. The clinical exam consists of facial, dental, and cervical evaluations including mandibular range of motion, Temporomandibular disorders Joint sound, and palpation of the orofacial muscles and temporomandibular joints (TMJ). Subjects are classified as TMD if they report pain in or around the temporomandibular joints or muscles of mastication for more than 3 months.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caloric Vestibular Neurostimulation</title>
            <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>0 participants received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Signs and Symptoms of Temporomandibular Disorder Based on Outcomes of Research Diagnostic Criteria (RDC) Exam</title>
          <description>RDC for Temporomandibular disorders (TMD) is a reliable &amp; valid system for diagnosis of TMD, utilizing clinical procedures, diagnostic algorithms, and a dual-axis assessment comprising symptom history and physical exam. Signs and symptoms were evaluated by a trained professional and the history was obtained through use of questionnaires. In all sections and scales the higher the number reported corresponds to the more pain being experienced, therefore, a worse outcome. The clinical exam consists of facial, dental, and cervical evaluations including mandibular range of motion, Temporomandibular disorders Joint sound, and palpation of the orofacial muscles and temporomandibular joints (TMJ). Subjects are classified as TMD if they report pain in or around the temporomandibular joints or muscles of mastication for more than 3 months.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours post-treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Caloric Vestibular Neurostimulation</title>
          <description>1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>0 participants received placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling Cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <description>Mild, transient</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Asma Khan</name_or_title>
      <organization>University of North Carolina</organization>
      <phone>919 537 3389</phone>
      <email>asma_khan@dentistry.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

